Share on StockTwits

Repligen Corp. (NASDAQ:RGEN) released its earnings data on Monday. The company reported $0.09 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.06 by $0.03, Stock Ratings Network.com reports. The company had revenue of $15.60 million for the quarter, compared to the consensus estimate of $14.90 million. During the same quarter last year, the company posted $0.14 earnings per share.

Shares of Repligen Corp. (NASDAQ:RGEN) opened at 21.29 on Monday. Repligen Corp. has a 52-week low of $9.41 and a 52-week high of $24.68. The stock has a 50-day moving average of $22.54 and a 200-day moving average of $17.71. The company has a market cap of $682.1 million and a P/E ratio of 38.09.

A number of research firms have recently commented on RGEN. Analysts at Janney Montgomery Scott initiated coverage on shares of Repligen Corp. in a research note on Thursday, June 26th. They set a “buy” rating and a $26.00 price target on the stock. Analysts at Jefferies Group raised their price target on shares of Repligen Corp. from $20.00 to $22.00 in a research note on Wednesday, June 4th. They now have a “buy” rating on the stock.

Repligen Corporation is a United States-based life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.